Health Canada has approved Rexulti (brexpiprazole) for agitation associated with Alzheimer’s disease-related dementia in patients with aggressive behavior. The treatment, co-developed by Otsuka Pharmaceuticals and Lundbeck, was recently approved by the U.S. Food and Drug Administration (FDA) for the same indication. “Today marks a major milestone…

The U.S. Food and Drug Administration (FDA) has approved Rexulti (brexpiprazole) to treat agitation associated with dementia due to Alzheimer’s disease. With this approval, Rexulti has now become the first and only therapy ever approved for this specific indication in the U.S. “Today marks a major milestone for…

Caring for a loved one with Alzheimer’s disease (AD) can be overwhelming. To help ease the caregiver burden — and ultimately benefit patients — a Florida-based company called VirtuALZ is offering a new virtual support program. Crafted specifically to support caregivers of patients who have Alzheimer’s and related…

A potential oral treatment for agitation due to Alzheimer’s dementia, AVP-786,  will continue in advanced clinical testing after a fuller analysis of data from two completed Phase 3 trials, Avanir Pharmaceuticals said. Their results were conflicting, with one trial showing a significant easing of agitated behaviors in patients given a…

A team led by a University of Washington (UW) School of Medicine scientist will use a $17.2 million National Institute on Aging (NIA) grant to study whether degenerative eye diseases are linked to Alzheimer’s disease (AD). The award went to Cecilia Lee, an assistant professor of ophthalmology. Along…

  New guidelines for Alzheimer’s disease patient care and caregiver support developed by the Alzheimer’s Association’s National Plan Care and Support Milestone Workgroup are detailed in a paper, “Report on milestones for care and support under the U.S. National Plan to Address Alzheimer’s Disease,” published…

The existence of specific and reliable biomarkers for Alzheimer’s disease are crucial to identifying individuals to enroll in clinical trials so that drugs can be tested and diseases can be detected as soon as possible. Facilitating clinical trial enrollment allows studies that are researching and developing therapies that stop or slow Alzheimer’s disease progression…